Literature DB >> 31012818

Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.

Joseph P Erinjeri1, Gabriel C Fine1, Gosse J Adema1, Muneeb Ahmed1, Julius Chapiro1, Martijn den Brok1, Rafael Duran1, Stephen J Hunt1, D Thor Johnson1, Jens Ricke1, Daniel Y Sze1, Beau Bosko Toskich1, Bradford J Wood1, David Woodrum1, S Nahum Goldberg1.   

Abstract

Interventional oncology is a subspecialty field of interventional radiology that addresses the diagnosis and treatment of cancer and cancer-related problems by using targeted minimally invasive procedures performed with image guidance. Immuno-oncology is an innovative area of cancer research and practice that seeks to help the patient's own immune system fight cancer. Both interventional oncology and immuno-oncology can potentially play a pivotal role in cancer management plans when used alongside medical, surgical, and radiation oncology in the care of cancer patients. © RSNA, 2019.

Entities:  

Mesh：

Year:  2019        PMID： 31012818      PMCID： PMC6604797          DOI： 10.1148/radiol.2019182326

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


  132 in total

1.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

Review 2.  Current status and perspectives of immune-based therapies for hepatocellular carcinoma.

Authors:  Maridi Aerts; Daphné Benteyn; Hans Van Vlierberghe; Kris Thielemans; Hendrik Reynaert
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Authors:  Cathy Q Fan; James M Crawford
Journal:  J Clin Exp Hepatol       Date:  2014-10-30

4.  Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation.

Authors:  Gaurav Kumar; S Nahum Goldberg; Svetlana Gourevitch; Tatyana Levchenko; Vladimir Torchilin; Eithan Galun; Muneeb Ahmed
Journal:  Radiology       Date:  2017-09-06       Impact factor: 11.105

5.  Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.

Authors:  Benjamin M Larimer; Eric Wehrenberg-Klee; Frank Dubois; Anila Mehta; Taylor Kalomeris; Keith Flaherty; Genevieve Boland; Umar Mahmood
Journal:  Cancer Res       Date:  2017-05-01       Impact factor: 12.701

6.  Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.

Authors:  Etienne Garin; Yan Rolland; Julien Edeline; Nicolas Icard; Laurence Lenoir; Sophie Laffont; Habiba Mesbah; Mathias Breton; Laurent Sulpice; Karim Boudjema; Tanguy Rohou; Jean-Luc Raoul; Bruno Clement; Eveline Boucher
Journal:  J Nucl Med       Date:  2015-02-12       Impact factor: 10.057

7.  Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.

Authors:  N J Lygidakis; P Kosmidis; N Ziras; J Parissis; E Kyparidou
Journal:  J Interferon Cytokine Res       Date:  1995-05       Impact factor: 2.607

8.  In situ tumor ablation creates an antigen source for the generation of antitumor immunity.

Authors:  Martijn H M G M den Brok; Roger P M Sutmuller; Robbert van der Voort; Erik J Bennink; Carl G Figdor; Theo J M Ruers; Gosse J Adema
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

9.  Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition.

Authors:  Gaurav Kumar; S Nahum Goldberg; Yuanguo Wang; Erik Velez; Svetlana Gourevitch; Eithan Galun; Muneeb Ahmed
Journal:  Eur Radiol       Date:  2016-06-10       Impact factor: 5.315

Review 10.  Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?

Authors:  Amol Mehta; Rahmi Oklu; Rahul A Sheth
Journal:  Gastroenterol Res Pract       Date:  2016-03-08       Impact factor: 2.260
View more
  13 in total

1.  Thermal ablation and systemic therapies in the metastatic liver: time for a "glocal" approach.

Authors:  Andrea Veltri; Marco Calandri
Journal:  Eur Radiol       Date:  2019-06-17       Impact factor: 5.315

2.  Thermal Ablation Induces Transitory Metastatic Growth by Means of the STAT3/c-Met Molecular Pathway in an Intrahepatic Colorectal Cancer Mouse Model.

Authors:  Haixing Liao; Muneeb Ahmed; Aurelia Markezana; Guohua Zeng; Matthias Stechele; Eithan Galun; S Nahum Goldberg
Journal:  Radiology       Date:  2019-12-17       Impact factor: 11.105

Review 3.  Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology.

Authors:  DaeHee Kim; Joseph P Erinjeri
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 4.  The evolution of interventional oncology in the 21st century.

Authors:  Thomas Helmberger
Journal:  Br J Radiol       Date:  2020-08-14       Impact factor: 3.039

5.  Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy.

Authors:  Bongseo Choi; Dong-Hyun Kim
Journal:  Adv Nanobiomed Res       Date:  2021-08-02

Review 6.  Radiomics in immuno-oncology.

Authors:  Z Bodalal; I Wamelink; S Trebeschi; R G H Beets-Tan
Journal:  Immunooncol Technol       Date:  2021-04-16

7.  Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.

Authors:  Antonia M Berz; Jessica G Santana; Simon Iseke; Moritz Gross; Vasily Pekurovsky; Fabian Laage Gaupp; Lynn J Savic; Tabea Borde; Luzie A Gottwald; Anne Marie Boustani; Bernhard Gebauer; MingDe Lin; Xuchen Zhang; Todd Schlachter; David C Madoff; Julius Chapiro
Journal:  J Vasc Interv Radiol       Date:  2022-03-26       Impact factor: 3.682

8.  Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model.

Authors:  Luzie A Doemel; Jessica G Santana; Lynn J Savic; Fabian M Laage Gaupp; Tabea Borde; Alexandra Petukhova-Greenstein; Ahmet S Kucukkaya; Isabel T Schobert; Charlie A Hamm; Bernhard Gebauer; John J Walsh; Irvin Rexha; Fahmeed Hyder; MingDe Lin; David C Madoff; Todd Schlachter; Julius Chapiro; Daniel Coman
Journal:  Eur Radiol       Date:  2021-10-31       Impact factor: 7.034

9.  Commentary on "CTLA-4 Blockade Suppresses Progression of Residual Tumours after Insufficient RFA".

Authors:  B Geboers; M R Meijerink
Journal:  Cardiovasc Intervent Radiol       Date:  2020-07-24       Impact factor: 2.740

10.  An Exploratory Analysis of Changes in Circulating Plasma Protein Profiles Following Image-Guided Ablation of Renal Tumours Provides Evidence for Effects on Multiple Biological Processes.

Authors:  Tze Min Wah; Jim Zhong; Michelle Wilson; Naveen S Vasudev; Rosamonde E Banks
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.